Verastem
The Senior Vice President of Regulatory Affairs and Quality provides enterprise-wide leadership for global regulatory strategy and product quality at Verastem Oncology. This executive role oversees regulatory activities and product quality oversight for the company's small molecule portfolio, ensuring compliance with global standards and supporting development, approval, and commercialization. The position requires building strong teams, strengthening global infrastructure, and driving cross-functional collaboration to achieve near-term milestones.
Headquarters
Needham Heights, Massachusetts, United States
Company Size
51-200 employees
Founded
2010
Verastem Oncology is a biopharmaceutical company focused on developing and delivering novel therapies for RAS/MAPK pathway-driven cancers. The company has advanced the first FDA-approved treatment for KRAS-mutant recurrent low-grade serous ovarian cancer and maintains a pipeline of small molecule inhibitors targeting KRAS G12D, RAF/MEK, and FAK pathways. Verastem leverages strategic collaborations and ongoing clinical trials to address significant unmet needs across multiple solid tumor types.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Verastem.
Senior Vice President, Regulatory Affairs
Mineralys Therapeutics
Vice President, Regulatory Affairs
Nuvalent, Inc.
Senior Vice President, Regulatory Affairs
Vir Biotechnology
Vice President, Medical Affairs, Clinical Operations & Regulatory Affairs
Dendreon Corporation
Vice President, Regulatory Affairs and Quality Assurance
Janux Therapeutics
Vice President of Quality & Regulatory Affairs
Clinical Dynamix